SYNTHESIS, TAUTOMERISM AND CALCULATIONS OF MESOMERIC BETAINES OF GUANINE

Andreas Schmidt* and Nikoloz Kobakhidze

Technical University of Clausthal, Institute of Organic Chemistry, Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany

<u>Abstract</u> - Reaction of purine-*N*-oxide (4) with 4-(dimethylamino)pyridine and acetyl chloride, followed by the treatment with hydrochloric acid gave the purine-pyridinium salt (6) which was deprotonated to the mesomeric betaine (7). Depending on the reaction conditions, 4-methylpyridine and pyridine, respectively, converted the nucleoside (8) into the pyridinium salts (9) and (10), or into the mesomeric betaines (11) and (12). According to calculations, the conjugated tautomers (A-D) of betaine (7) are more stable than the cross-conjugated tautomer (7E).

Base-mispairings of nucleobases due to the formation of tautomers are of interest since the discovery of the *Watson-Crick* base-pairs in DNA.¹ Their role in mutations, cancer development and other diseases has been discussed intensively.² An additional impetus was the discovery of the posttranscriptionally modified, mutagenic and self-complementary nucleoside 7-methylguanosine (1), isolated from distinct types of RNA (*r*-RNA, archaea, bacterial, and eucaryotic *t*-RNA³) and identified as 5'-terminal cap structure of *messenger*-RNA.⁴ In *t*-RNAs, 7-methylguanosine (1) forms nonstandard base-triplets and base-mispairs. Examples are m⁷G=G=C and m⁷G=A which stabilize the tertiary structure of the polynucleotide chains.⁵ Obviously, on converting this nucleobase into a mesomeric betaine, biologically important horizontal (*Watson-Crick* and *Hoogsteen* base pairing) as well as vertical interactions (π -stacking) change. The cancerostatic, antimicrobial and antiviral guanin-7-oxide (2), produced by *Streptomyces* species,⁶ is an additional example of a betainic nucleobase.



Scheme 1

The purines (1) and (2) belong to the class of conjugated mesomeric betaines (CMB) which contrasts to cross-conjugated (CCMB) and pseudo-cross-conjugated (PCCMB) systems known in heterocyclic chemistry.⁷ In continuation of our work on mesomeric betaines and betainic nucleobases⁸ we became interested in studying a model compound of 7-methylguanosine which in principle could adopt different tautomers and types of conjugation. We report here the syntheses and the results of semiempirical calculations of such novel betainic purine derivatives.

Guanine (3) was oxidized at N-3 by hydrogen peroxide in the presence of trifluoroacetic acid to yield the conjugated heterocyclic *N*-ylide (4).⁹ Acetylation of 4 with acetyl chloride in the presence of 4-(dimethylamino)pyridine over a period of 20 h at room temperature forms 1-(2-acetylamino-6-oxo-6,9-dihydro-1*H*-purin-8-yl)-4-(dimethylamino)pyridinium chloride (5) in satisfactory yield. The chloride 5 was almost quantitatively converted into 1-(2-amino-6-oxo-6,9-dihydro-1*H*-purin-8-yl)-4-(dimethylamino)pyridinium chloric acid at 80°C. Deprotonation of aqueous solutions of **6** was accomplished by Amberlite IRA-93 in its hydroxy form to give the slightly yellow mesomeric betaine 8-[4-(dimethylamino)pyridinio]-2-aminopurin-6-olate (7) in quantitative yield.



This procedure could not be applied to heteroaromatics that are less basic than 4-(dimethylamino)pyridine. Pyridine and 4-methylpyridine, however, are able to substitute C(8) of 8-bromoguanosine which is - in contrast to the corresponding guanine - readily available by bromination of guanosine in water (Scheme 3).¹⁰ The reactions afford pure anhydrous solvents and prolonged reaction times. At moderate temperatures, the 1-(guanosin-8-yl)-pyridinium salts (9) and (10) were formed as intensely red and very sparcely soluble compounds (55 and 25%, respectively). On treatment of aqueous solutions of 9^{11} and 10^{12} with the anion exchange resin Amberlite IRA-93 in its hydroxy form, these cationic systems were quantitatively converted into the orange mesomeric betaines (11)¹³ and (12)¹⁴; no traces of the betainic guanosines (15) and (16) were isolated. Reaction of 8 with pyridine and 4-methylpyridine, respectively, at reflux temperature over a period of 8 h gave the mesomeric betaines (11) and (12) in one step after column chromatography (silica gel, 1. ethyl acetate, 2. MeOH). Treatment of 11 and 12 with 1N hydrochloric acid at room temperature and evaporation gave the yellow colored chlorides (13) and (14) in 94 and 96% yield, respectively.



On converting the betaines into the cations all ¹H NMR resonance frequencies except for the α -position of the pyridinium rings shift considerably downfield. As a representative example, the chemical shift changes of the pyridinium substituted derivatives (11) and (13) are given in Table 1.

Table 1. ¹H NMR chemical shift changes [ppm] in DMSO- d_6 at rt on conversion of the mesomeric betaine (11) into cation (13).

	11	13	Δδ
NH	10.40	11.82	+1.42
NH_2	6.03	7.91	+1.87
α-H	9.71	9.68	-0.03
β-Η	8.10	8.20	+0.10
γ-H	8.48	8.65	+0.17



Although five tautomeric forms (A-E) of the mesomeric betaines (7, 11, and 12) can be formulated (Scheme 4), the ¹H NMR spectra in DMSO-d₆ at room temperature display only one tautomer.



Interestingly, the structures $(\mathbf{A} - \mathbf{D})$ are conjugated mesomeric betaines, whereas **E** belongs to the class of cross-conjugated mesomeric betaines. Thus, a closer inspection of the canonical formulae reveal common atoms for either positive and negative charge in the CMBs $(\mathbf{A} - \mathbf{D})$, whereas in the CCMB (**E**) the charges are exclusively delocalized in separated parts of the common π -electron system. There are specific associations of various types of dipoles with the types of conjugation in heterocyclic mesomeric betaines.⁷ Characteristically for the class of conjugated mesomeric betaines, the dipole (**I**) can be dissected from the canonical formulae of tautomer A, whereas the vinyloge of a characteristic dipole increment of cross-conjugated mesomeric betaines (**II**) can be found in tautomer (**E**). **A** is a CMB isoconjugate to the even nonalternant hydrocarbon 4-methyl-2-phenyl-1*H*-indene dianion (**III**) and thus belongs to class 4, whereas the CCMB (**E**) is a member of class 12 of heterocyclic mesomeric betaines.⁷



Figure 1

According to a PM3 calculation,¹⁵ **A** is the most stable and **E** the most unstable tautomer which explains the finding that the betaines (**15**) and (**16**) were not formed (Table 2). As to be expected, the calculation leads to essentially planar molecules in either case as the most stable conformers [$\tau = 0.19^{\circ}$]. The calculated frontier orbital profiles reflect the distinct types of conjugation. The LUMOs of the tautomers (**7A**) and (**7E**) are essentially located at the nitrogen atom and the α - and γ -atoms of the pyridinium rings. In the CCMB (**7E**), however, the positive moiety of the molecule is joined to a nodal position of the HOMO which characteristically is located in the anionic portion of the betaine (Figure 3). As a consequence, C(8) serves as an isolator and the positive and the negative charges are separated in the ground state of the molecule. Correspondingly, the permanent dipole moment of **7E** is the largest of all tautomers (Table 2). In contrast to that, C(8) of **7A** is an active position of the HOMO, so that the charges are in mutual conjugation (Figure 2). Consequently, the permanent dipole moment is considerably smaller.



Table 2. Heats of formation of the tautomers (**7A-E**) according to a PM3 calculation. Permanent dipole moments.

Tautomer	∆H _f (PM3) [KJ/mol]	Calcd dipole moment μ [D]
7A	249.20	9.86
7B	300.60	13.40
7C	261.28	12.79
7D	268.51	11.64
7E	356.75	20.79

As a conclusion, similar to the biologically important mesomeric betaine 7-methylguanosine m^7G isolated from RNA the model compounds described here adopt tautomers which are conjugated systems. The most stable tautomer is a conjugated mesomeric betaine with the *Watson-Crick* binding site of unmodified guanine. In contrast to this, the most unstable tautomer has the binding site of m^7G , but is a cross-conjugated mesomeric betaine.

ACKNOWLEDGMENTS.

Dr. M. K. Kindermann (University of Greifswald, Germany) and Dr. M. Drache (Technical University of Clausthal, Germany) are acknowledged for performing the calculations. The Deutsche Forschungsgemeinschaft DFG and the Fonds der Chemischen Industrie FCI are gratefully acknowledged for financial support.

REFERENCES AND NOTES

- 1. J. D. Watson and F. H. C. Crick, *Nature*, 1953, **171**, 737.
- D. Venkateswarlu, R. H. D. Lyngdoh, and M. Bansal, J. Chem. Soc., Perkin Trans 2, 1997, 621; D. Venkateswarlu and R. H. D. Lyngdoh, J. Chem. Soc., Perkin Trans.2, 1995, 839; H. Echols and M. F. Goodman, Annu. Rev. Biochem., 1991, 60, 477; L.-C. Sowers, M. F. Goodman, R. Eritja, B. Kaplan, and G. V. Fazakerley, J. Mol. Biol., 1989, 205, 437; W. Saenger, Principles of Nucleic Acid Structure, in: 'Springer Advanced Texts in Chemistry,' ed. by C. R. Cantor, Springer-Verlag, New York, 1984.
- Y. Kuchino, M. Ihara, Y. Yabusaki, and S. Nishimura, *Nature*, 1982, **298**, 684; C. W. Gehrke and K. C. Kuo, *J. Chromatogr.*, 1989, **471**, 3; V. S. Zueva, A. S. Mankin, W. D. Bogdanov, D. Thurlow, and R. A. Zimmermann, *FEBS Lett.*, 1985, **188**, 233; J. P. Cecchini and R. Miassod, *Eur. J. Biochem.*, 1979, **98**, 203; J. A. Haines, C. B. Reese, and L. Todd, *J. Chem. Soc.*, 1962, 5281; C. G. Edmons, P. F. Crain, R. Gupta, T. Hashizume, C. H. Hocart, J. A. Kowalak, S. C. Pomerantz, K. O. Stetter, and J. A. McCloskey, *J. Bacteriol.*, 1991, **173**, 3138.
- 4. G. Dirheimer, in 'Modified Nucleosides and Cancer;' ed. by G. Glass, Springer-Verlag, Berlin Heidelberg, 1983, pp. 15 46; R. Liou and T. Blumenthal, *Mol. Cell Biol.*, 1990, **10**, 1764.
- 5. S.-H. Kim, *Prog. Nucl. Acid Res. Mol. Biol.*, 1976, **17**, 181; J. L. Sussman, S. R. Holbrook, R. Wade Warrant, G. M. Church, and S.-H. Kim, *J. Mol. Biol.*, 1978, **123**, 607.
- D. L. Kern, G. C. Hokanson, J. C. French, and N. K. Dally, J. Antibiot., 1985, 38, 572; M. Kitahara, K. Ishii, Y. Kumada, T. Shiraishi, T. Furuta, T. Miwa, H. Kawaharada, and K. Watanabe, J. Antibiot., 1985, 38, 972; M. Kitahara, K. Ishii, H. Kawaharada, K. Watanabe, T. Suga, T. Hirata, and S. Nakamura, J. Antibiot., 1985, 38, 977; M. Nishii, J. Inagaki, F. Nohara, K. Isono, H. Kusakabe, K. Kobayashi, T. Sakurai, S. Koshimura, S. K. Sethi, and J. A. McCloskey, J. Antibiot., 1985, 38, 1440.
- 7. W. D. Ollis, S. P. Stanforth, and C. A. Ramsden, *Tetrahedron*, 1985, 41, 2239.
- A. Schmidt, N. Kobakhidze, and M. K. Kindermann, J. Chem. Soc., Perkin Trans 1, 2002, 982; A. Schmidt, T. Mordhorst, and T. Habeck, Org. Lett., 2002, 4, 1375; A. Schmidt, P. Vainiotalo, M. K. Kindermann, and M. Nieger, Heterocycles, 2002, 57, 615; A. Schmidt, N. Kobakhidze, and M. K. Kindermann, Chem. Lett., 2001, 4, 348; A. Schmidt and M. Nieger, Heterocycles, 2001, 55, 827; A. Schmidt and M. K. Kindermann, Bull. Chem. Soc. Jpn., 2001, 74, 2379; A. Schmidt, M. K. Kindermann, P. Vainiotalo, and M. Nieger, J. Org. Chem., 1999, 64, 9499; A. Schmidt, M. K. Kindermann, and M. Nieger, Heterocycles, 1999, 51, 237; A. Schmidt and M. K. Kindermann, J. Org. Chem., 1997, 62, 3910.
- 9. J. C. Parham, T. G. Winn, and G. B. Brown, *J. Org. Chem.*, 1971, **36**, 2639; N. J. M. Birdsall, U. Wölcke, T.-C. Lee, and G. B. Brown, *Tetrahedron*, 1971, **27**, 5969.
- 10. R. Shapiro and S. C. Agarwal, Biochem. Biophys. Res. Commun., 1966, 24, 401.
- 11. ¹H NMR: δ = 10.62 (s, 1H; NH), 9.68 (m, 2H; α-H), 8.48 (m, 1H; γ-H), 8.09 (m, 2H; β-H), 6.08 (s, 2H; NH₂), 5.68 (d, J = 8.0 Hz, 1H; CH), 5.46, (m, 1H; OH), 5.14 (m, 1H; OH), 4.40 (m, 1H; OH), 4.12 (m, 1H; CH), 3.90 (m, 1H; CH), 3.64 (m, 1H; CH), 3.54 (m, 1H; CH) ppm; IR: 3414, 3100, 1688, 1480, 1373, 1234 cm⁻¹; UV (MeOH): λ_{max} = 656, 598, 422 nm.

- 12. ¹H NMR: δ = 11.09 (s, 1H; NH), 9.57 (m, 2H; α-H), 7.94 (m, 2H; β-H), 6.60 (s, 2H; NH₂), 5.68 (d, J = 7.9 Hz, 1H; CH), 5.48 (m, 1H; OH), 5.13 (m, 1H; OH), 4.99 (m, 1H; OH), 4.11 (m, 1H; CH), 3.86 (m, 1H; CH), 3.62 (m, 1H; CH), 3.62 (m, 1H; CH), 3.53 (m, 1H; CH), 2.62 (s, 3H; Me); IR: 3391, 1676, 1465, 1223 cm⁻¹; UV (MeOH): λ_{max} = 656, 576, 412, 248 nm.
- 13. ¹H NMR: δ = 10.40 (s, 1H; NH), 9.71 (m, 2H; α-H), 8.48 (m, 1H; γ-H), 8.10 (m, 2H; β-H), 6.03 (s, 2H; NH₂); ¹³C NMR: δ = 191.77, 161.57, 158.10, 151.97, 144.36, 138.10, 128.00, 120.53 ppm; IR: 3417, 3132, 1668.0, 1482.5, 1371.3 cm⁻¹; UV (MeOH): $\lambda_{max} = 658, 600, 420$ nm.
- 14. ¹H NMR: δ = 10.53 (s, 1H; NH), 9.56 (m, 2H; α-H), 7.93 (m, 2H; β-H), 5.87 (s, 2H; NH₂), 2.62 (s, 3H; Me) ppm; UV (MeOH): λ_{max} = 408, 272, 246 nm.
- 15. Semiempirical calculations were carried out using MOPAC 6.0^{16} on a IBM workstation RS/6000, AIX 4.3 to perform the PM3 calculations. The structures were first optimized with the default gradient requirements and subsequently refined with the options GNORM = 0.01, SCFCRT = 1 x 10^{-10} . The absolute minima were proved by a force calculation.
- 16. J. J. P. Stewart, QPCE, Department of Chemistry, Bloomington, IN 1989; J. J. P. Stewart, J. Comput. Chem., 1989, **10**, 209.